Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Stock Performance

Check-Cap stock opened at $0.68 on Thursday. The stock has a 50-day simple moving average of $0.80 and a 200 day simple moving average of $1.01. The stock has a market capitalization of $3.95 million, a P/E ratio of -0.23 and a beta of 0.20. Check-Cap has a 52 week low of $0.56 and a 52 week high of $3.04.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.